Loading...
Rhythm Biosciences Limited
RHY.AX•ASX
Healthcare
Medical - Diagnostics & Research
A$0.06
A$0.00(0.00%)
Rhythm Biosciences Limited (RHY.AX) Financial Performance & Income Statement Overview
Review Rhythm Biosciences Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-45.41%
↓ 45.41%
Operating Income Growth
41.89%
↑ 41.89%
Net Income Growth
16.56%
↑ 16.56%
Operating Cash Flow Growth
11.79%
↑ 11.79%
Operating Margin
-62.71%
↓ 62.71%
Gross Margin
71.87%
↑ 71.87%
Net Profit Margin
-38.95%
↓ 38.95%
ROE
-75.75%
↓ 75.75%
ROIC
-70.91%
↓ 70.91%
Rhythm Biosciences Limited (RHY.AX) Income Statement & Financial Overview
Review Rhythm Biosciences Limited's (RHY.AX) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $2.42M | $1.69M | $374899.00 | $2.72M |
| Cost of Revenue | $1.21M | $102587.00 | $96183.00 | $93194.00 |
| Gross Profit | $1.21M | $1.59M | $278716.00 | $2.63M |
| Gross Profit Ratio | $0.50 | $0.94 | $0.74 | $0.97 |
| R&D Expenses | $1.13M | $1.21M | $1.43M | $2.22M |
| SG&A Expenses | $1.55M | $1.46M | $3.51M | $4.20M |
| Operating Expenses | $2.68M | $5.72M | $4.94M | $6.42M |
| Total Costs & Expenses | $3.89M | $5.82M | $5.03M | $6.51M |
| Interest Income | $14200.00 | $38082.00 | $119593.00 | $108677.00 |
| Interest Expense | $3143.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $7419.00 | $102587.00 | $96183.00 | $93194.00 |
| EBITDA | -$2.77M | -$5.68M | -$4.82M | -$3.69M |
| EBITDA Ratio | -$1.14 | -$3.38 | -$13.17 | -$2.36 |
| Operating Income | -$3.89M | -$5.82M | -$5.03M | -$6.51M |
| Operating Income Ratio | -$1.61 | -$3.44 | -$13.42 | -$2.39 |
| Other Income/Expenses (Net) | $1.13M | $38082.00 | $1.86M | $123677.00 |
| Income Before Tax | -$2.77M | -$5.78M | -$4.91M | -$6.39M |
| Income Before Tax Ratio | -$1.14 | -$3.42 | -$13.10 | -$2.35 |
| Income Tax Expense | $0.00 | -$1.69M | -$374602.00 | -$2.71M |
| Net Income | -$2.77M | -$4.09M | -$4.54M | -$3.68M |
| Net Income Ratio | -$1.14 | -$2.42 | -$12.11 | -$1.35 |
| EPS | -$0.01 | -$0.02 | -$0.02 | -$0.02 |
| Diluted EPS | -$0.01 | -$0.02 | -$0.02 | -$0.02 |
| Weighted Avg Shares Outstanding | $235.45M | $225.88M | $221.92M | $221.07M |
| Weighted Avg Shares Outstanding (Diluted) | $235.44M | $225.88M | $221.92M | $221.07M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan